SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Celera Genomics (CRA)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Raymond Clutts who started this subject10/1/2001 10:55:17 AM
From: Raymond Clutts  Read Replies (1) of 746
 
From an article this morning by one of the resident chart gurus, Helene Meisler at The Street.com, we have the following:

In the biotechs, I can see some resistance in Celera Genomics (CRA:NYSE - news - commentary - research) in this area as well. It's not as blatant as what we saw in the Target chart, but it's there. This past spring's low was in the mid-$20s, so that's resistance. The August low, before the big plunge, was just above $25, so that's resistance as well. But if we draw the big downtrend line from $50 in June, you can see it's now approaching the downtrend line as well. So Celera appears to have seen the bulk of its rally too.

Celera Genomics
It seems to be approaching a downtrend

thestreet.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News